Cited by 109vaccines and immunoinformatics approachesBiosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

DEGROOT, A, MCMURRY, J, MOISE, L·2008·Current Opinion in Pharmacology

DOI 10.1016/j.coph.2008.08.002

Open this paper in CoChat — free account

Abstract

Immunogenicity can be a major obstacle to successful protein drug therapy. Antidrug antibodies may neutralize therapeutic function, influence pharmacokinetics and, in some cases, lead to severe adverse effects. These effects depend on factors including dose, regimen, delivery route and contaminants, among others. Importantly, immunogenicity is a consideration that is better addressed during preclinical development before complications arise in clinical trials or following licensure. This article will address the development and application of computational tools for immunogenicity assessment of protein therapeutics, and validation of those predictions using peripheral blood from exposed subjects or alternative in vivo methods.

Integrity signals

Registry

Crossref · 10.1016/j.coph.2008.08.002

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0207 · Cited by 1,483
Natural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature reviews. Immunology · doi:10.1038/nri1032 · Cited by 1,319
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
Casadevall, N., Nataf, J., Viron, B. M., Kolta, A. M., Kiladjian, J., Martin-Dupont, P., Michaud, P. A., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,244
Multiple defects in innate and adaptive immunologic function in NOD/LtSz- scid mice.
Shultz, L. D., Schweitzer, P. A., Christianson, S. W., Gott, B., Schweitzer, I. B., Tennent, B. J., McKenna, S., Mobraaten, L. E., Rajan, T. V., Greiner, D. L., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.180 · Cited by 1,224
Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice
Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.-C., Lanzavecchia, A., & Manz, M. G. (2004) · Science · doi:10.1126/science.1093933 · Cited by 989
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Ishikawa, F., Yasukawa, M., Lyons, B. L., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 933
Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
Southwood, S., Sidney, J., Kondo, A., del Guercio, M., Appella, E., Hoffman, S. L., Kubo, R. T., Chesnut, R. W., Grey, H. M., & Sette, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3363 · Cited by 665
Immunogenicity of protein therapeutics
Groot, A. S. D., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 544
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
Groot, A. S. D., Moise, L., McMurry, J. A., Wambre, E. R., Overtvelt, L. V., Moingeon, P. E., Scott, D. W., & Martin, W. D. (2008) · Blood · doi:10.1182/blood-2008-02-138073 · Cited by 392
Self-citation
A Novel Mechanism of Action for Anti-Thymocyte Globulin
Lopez, M., Clarkson, M. R., Albin, M., Sayegh, M. H., & Najafian, N. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050422 · Cited by 365

Flagged first, then by citations

Show all 55 references

Sorted by citations

Stability of Protein Pharmaceuticals: An Update
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,140
The immunogenicity of humanized and fully human antibodies
Harding, F., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 743
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 525
Monoclonal antibody therapeutics: history and future
Buss, N. A. P. S., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 480
Therapeutic Proteins
Dimitrov, D. S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 384
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 342
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & Groot, A. S. D. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
Ponce, R. A., Abad, L. W., Amaravadi, L. S., Gelzleichter, T. R., Gore, E. R., Green, J., Gupta, S., Herzyk, D. J., Hurst, C. H., Ivens, I. A., et al. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.03.012 · Cited by 271
Adnectins: engineered target-binding protein therapeutics
Lipovšek, D. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq097 · Cited by 242
The Key Role of Genomics in Modern Vaccine and Drug Design for Emerging Infectious Diseases
Seib, K. L., Dougan, G., & Rappuoli, R. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000612 · Cited by 203
“High‐risk” host cell proteins (HCPs): A multi‐company collaborative view
Jones, M., Palackal, N. T., Wang, F., Gaza‐Bulseco, G., Hurkmans, K., Zhao, Y., Chitikila, C., Clavier, S., Liu, S., Menesale, E. B., et al. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27808 · Cited by 163
Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice
Filipe, V., Jiskoot, W., Basmeleh, A., Halim, L. A., Schellekens, H., & Brinks, V. (2012) · mAbs · doi:10.4161/mabs.22066 · Cited by 156
Immunogenicity of Protein Pharmaceuticals
Dingman, R. K., & Balu‐Iyer, S. V. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.014 · Cited by 162
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
Jawa, V., Terry, F. E., Gokemeijer, J., Mitra‐Kaushik, S., Roberts, B., Tourdot, S., & Groot, A. S. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01301 · Cited by 163
Emerging Vaccine Informatics
He, Y. O., Rappuoli, R., Groot, A. S. D., & Chen, R. T. (2010) · BioMed Research International · doi:10.1155/2010/218590 · Cited by 154
Therapeutic antibodies, vaccines and antibodyomes
Dimitrov, D. S. (2010) · mAbs · doi:10.4161/mabs.2.3.11779 · Cited by 141
Engineering the variable region of therapeutic IgG antibodies
Igawa, T., Tsunoda, H., Kuramochi, T., Sampei, Z., Ishii, S., & Hattori, K. (2011) · mAbs · doi:10.4161/mabs.3.3.15234 · Cited by 140
Immunogenicity assessment during the development of protein therapeutics
Rosenberg, A. S., & Sauna, Z. E. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12810 · Cited by 131
The Immunogenicity of Antibody Aggregates in a Novel Transgenic Mouse Model
Bessa, J., Boeckle, S., Beck, H., Buckel, T., Schlicht, S., Ebeling, M., Kiialainen, A., Koulov, A. V., Boll, B., Weiser, T. W., et al. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1627-0 · Cited by 124
Evaluating and mitigating the immunogenicity of therapeutic proteins
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.008 · Cited by 118
Molecular engineering of antibodies for therapeutic and diagnostic purposes
Ducancel, F., & Muller, B. H. (2012) · mAbs · doi:10.4161/mabs.20776 · Cited by 113
Prediction of Immunogenicity of Therapeutic Proteins
Bryson, C. J., Jones, T. D., & Baker, M. (2010) · BioDrugs · doi:10.2165/11318560-000000000-00000 · Cited by 102
Therapeutic Antibodies Against Cancer
Adler, M. J., & Dimitrov, D. S. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.013 · Cited by 94
Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics
Wullner, D., Zhou, L., Bramhall, E., Kuck, A. J., Goletz, T. J., Swanson, S. J., Chirmule, N. B., & Jawa, V. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.06.018 · Cited by 86
Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions
Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85
Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen
Toda, M., Reese, G., Gadermaier, G., Schulten, V. M. J., Lauer, I., Egger, M., Briza, P., Randow, S., Wolfheimer, S., Kigongo, V., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.020 · Cited by 83
CD4+ T Cell Epitope Discovery and Rational Vaccine Design
Rosa, D. S., Ribeiro, S. P., & Cunha‐Neto, E. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0067-0 · Cited by 84
Low immunogenicity predicted for emerging avian-origin H7N9
Groot, A. S. D., Ardito, M. T., Terry, F. E., Levitz, L., Ross, T. M., Moise, L., & Martin, W. D. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24939 · Cited by 74
Self-citation
Immunogenicity risk assessment of synthetic peptide drugs and their impurities
Groot, A. S. D., Roberts, B., Mattei, A. E., Lélias, S., Boyle, C., & Martin, W. D. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103714 · Cited by 73
A Descriptor Set for Quantitative Structure‐property Relationship Prediction in Biologics
Sankar, K., Trainor, K., Blazer, L. L., Adams, J., Sidhu, S. S., Day, T., Meiering, E. M., & Maier, J. K. X. (2022) · Molecular Informatics · doi:10.1002/minf.202100240 · Cited by 72
Human immunity in vitro — Solving immunogenicity and more
Giese, C., & Marx, U. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.011 · Cited by 65
Therapeutic proteins: developments, progress, challenges, and future perspectives
Kumar, V., Barwal, A., Sharma, N., Mir, D. S., Kumar, P., & Kumar, V. (2024) · 3 Biotech · doi:10.1007/s13205-024-03958-z · Cited by 62
Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins
Brinks, V., Weinbuch, D., Baker, M., Dean, Y. D., Stas, P., Kostense, S., Rup, B. J., & Jiskoot, W. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1062-z · Cited by 60
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
Sampei, Z., Haraya, K., Tachibana, T., Fukuzawa, T., Shida-Kawazoe, M., Gan, S. W., Shimizu, Y., Ruike, Y., Feng, S., Kuramochi, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209509 · Cited by 57
Living in LALA land? Forty years of attenuating Fc effector functions
Hale, G. (2024) · Immunological Reviews · doi:10.1111/imr.13379 · Cited by 55
OptMAVEn-2.0: De novo Design of Variable Antibody Regions against Targeted Antigen Epitopes
Chowdhury, R., Allan, M. F., & Maranas, C. D. (2018) · Antibodies · doi:10.3390/antib7030023 · Cited by 55
In vitro models for immunogenicity prediction of therapeutic proteins
Groell, F., Jordan, O., & Borchard, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.008 · Cited by 53
Analytical aspects of biosimilarity issues of protein drugs
Kálmán-Szekeres, Z., Olajos, M., & Ganzler, K. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.04.037 · Cited by 53
Translational strategies for development of monoclonal antibodies from discovery to the clinic
Tabrizi, M. A., Bornstein, G. G., Klakamp, S. L., Drake, A. W., Knight, R., & Roskos, L. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.008 · Cited by 54
Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters
Barbosa, M. D. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.011 · Cited by 52
Challenges and Opportunities in Absorption, Distribution, Metabolism, and Excretion Studies of Therapeutic Biologics
Xu, X., & Vugmeyster, Y. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9388-8 · Cited by 50
Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice
Uchino, T., Miyazaki, Y., Yamazaki, T., & Kagawa, Y. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12765 · Cited by 49
Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods
Pérez, A.-M. W., Lorenzen, N., Vendruscolo, M., & Sormanni, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1450-1_4 · Cited by 43
Highlights on the Application of Genomics and Bioinformatics in the Fight Against Infectious Diseases: Challenges and Opportunities in Africa
Bah, S. Y., Morang’a, C. M., Kengne-Ouafo, J. A., Amenga-Etego, L. N.-K., & Awandare, G. A. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00575 · Cited by 42
Fasciola hepatica: The therapeutic potential of a worm secretome
Robinson, M. W., Dalton, J. P., O’Brien, B. A., & Donnelly, S. (2012) · International Journal for Parasitology · doi:10.1016/j.ijpara.2012.11.004 · Cited by 45
Can we prevent immunogenicity of human protein drugs?
Scott, D. W., & Groot, A. S. D. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.117564 · Cited by 41
MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity
Sekiguchi, N., Kubo, C., Takahashi, A., Muraoka, K., Takeiri, A., Ito, S., Yano, M., Mimoto, F., Maeda, A., Iwayanagi, Y., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1518888 · Cited by 36
Humanization and Simultaneous Optimization of Monoclonal Antibody
Kuramochi, T., Igawa, T., Tsunoda, H., & Hattori, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_7 · Cited by 36
Nonclinical development of biopharmaceuticals
Baumann, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.013 · Cited by 33
Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies
Kumar, S., Mitchell, M. A., Rup, B., & Singh, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23169 · Cited by 33
Monoclonal antibody based radiopharmaceuticals for imaging and therapy
Lin, M., Paolillo, V., Le, D., Macapinlac, H. A., & RAVIZZINI, G. C. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100796 · Cited by 32
A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora
Belén, L. H., Lissabet, J. F. B., Rangel‐Yagui, C. D. O., Effer, B. R., Monteiro, G., Pessoa, A., & Farías, J. G. (2019) · Biologicals · doi:10.1016/j.biologicals.2019.03.003 · Cited by 31
Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products
Jankowski, W., Park, Y., McGill, J. R., Maraskovsky, E., Hofmann, M., Diego, V. P., Luu, B. W., Howard, T. E., Kellerman, R., Key, N. S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030452 · Cited by 32
Current In Vitro Assays for Prediction of T Cell Mediated Immunogenicity of Biotherapeutics and Manufacturing Impurities
Duke, B. R., & Mitra‐Kaushik, S. (2019) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-019-09412-5 · Cited by 30
Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions
Knödler, M., & Buyel, J. F. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107683 · Cited by 29
Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics
Barbosa, M. D. F. S., Kumar, S., Loughrey, H. C., & Singh, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.003 · Cited by 30
Biosimilar recombinant follicle stimulating hormones in infertility treatment
Santi, D., & Simoni, M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.925872 · Cited by 29
Universal Immunoassay Applied During Early Development of Large Molecules to Understand Impact of Immunogenicity on Biotherapeutic Exposure
Bautista, A., Salimi-Moosavi, H., & Jawa, V. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9403-0 · Cited by 29
ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans
Jing, L., McCaughey, S. M., Davies, D. H., Chong, T. M., Felgner, P. L., Rosa, S. C. D., Wilson, C. B., & Koelle, D. M. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.05.011 · Cited by 27
Development of a FRET-Based Assay for Analysis of mAbs Internalization and Processing by Dendritic Cells in Preclinical Immunogenicity Risk Assessment
Wen, Y., Cahya, S., Zeng, W., Lin, J., Wang, X., Liu, L., Malherbe, L. P., Siegel, R. W., Ferrante, A., & Kaliyaperumal, A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00444-1 · Cited by 29
Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem
Ulitzka, M., Carrara, S. C., Grzeschik, J., Kornmann, H., Hock, B. M., & Kolmar, H. (2020) · Protein Engineering Design and Selection · doi:10.1093/protein/gzaa025 · Cited by 31
Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis
Santos, M. L. B., Nico, D., de Oliveira, F. A., Barreto, A. S., de Sousa, I. P., Carrillo, E., Moreno, J., Luca, P. M. D., Morrot, A., Rosa, D. S., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00227 · Cited by 26
Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations
Johnson, R., & Jiskoot, W. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23248 · Cited by 25
An integrated approach for characterizing immunogenic responses toward a bispecific antibody
Cohen, S., Chung, S., Spiess, C., Lundin, V., Stefanich, E. G., Laing, S. T., Clark, V., Brumm, J., Zhou, Y., Huang, C., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1944017 · Cited by 24
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A
Koga, H., Yamano, T., Betancur, J., Nagatomo, S., Ikeda, Y., Yamaguchi, K., Nabuchi, Y., Sato, K., Teranishi-Ikawa, Y., Sato, M., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2222441 · Cited by 23
Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs
Jawa, V., Maamary, J., Swanson, M. D., Zhang, S., & Montgomery, D. L. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.01.032 · Cited by 22
Humanization and Simultaneous Optimization of Monoclonal Antibody
Kuramochi, T., Igawa, T., Tsunoda, H., & Hattori, K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_9 · Cited by 21
Improving TNF as a cancer therapeutic: Tailor‐made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects
Gerspach, J., Pfizenmaier, K., & Wajant, H. (2009) · BioFactors · doi:10.1002/biof.50 · Cited by 20
Bridging Innate and Adaptive Antitumor Immunity Targeting Glycans
Pashov, A. D., Monzavi‐Karbassi, B., Raghava, G. P. S., & Kieber‐Emmons, T. (2010) · BioMed Research International · doi:10.1155/2010/354068 · Cited by 18
Nanovesicles released by OKT3 hybridoma express fully active antibodies
Logozzi, M., Raimo, R. D., Properzi, F., Barca, S., Angelini, D. F., Mizzoni, D., Falchi, M., Battistini, L., & Fais, S. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1852401 · Cited by 18
Surface Plasmon Resonance for Therapeutic Antibody Characterization
Davidoff, S. N., Ditto, N. T., Brooks, A. E., Eckman, J. W., & Brooks, B. D. (2015) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-2617-6_3 · Cited by 16
J‐LEAPS peptide and LEAPS dendritic cell vaccines
Rosenthal, K. S., Taylor, P. R., & Zimmerman, D. H. (2011) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2011.00278.x · Cited by 16
Immunoinformatics and reverse vaccinology methods to design peptide-based vaccines
Sharma, V., Singh, S., Ratnakar, T. S., & Prajapati, V. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90264-9.00029-5 · Cited by 15
Pioneering Use of the Cloud for Development of Collaborative Drug Discovery (CDD) Database
Ekins, S., Hohman, M. M., & Bunin, B. A. (2011) · doi:10.1002/9781118026038.ch21 · Cited by 14
Advances in Predicting and Manipulating the Immunogenicity of Biotherapeutics and Vaccines
Flower, D. R. (2009) · BioDrugs · doi:10.2165/11317530-000000000-00000 · Cited by 13
Product-Related Factors and Immunogenicity of Biotherapeutics
Krishna, M. (2019) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-019-09423-2 · Cited by 12
Immunogenicity assessment of fungal l-asparaginases: an in silico approach
Belén, L. H., Lissabet, J. F. B., Rangel‐Yagui, C. D. O., Monteiro, G., Pessoa, A., & Farías, J. G. (2020) · SN Applied Sciences · doi:10.1007/s42452-020-2021-z · Cited by 12
Insights on the Formulation of Recombinant Proteins
Ribeiro, R., Abreu, T. R., Silva, A. C., Gonçalves, J., & Moreira, J. N. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_119 · Cited by 11
Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study
Liao, K., Chen, K., Brett, S. J., Gehman, A., Schwartz, A. M., Gunn, G. R., & DeWall, S. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249049 · Cited by 8
Formulation development of small and large volume injections
Kamat, M. S., & DeLuca, P. P. (2012) · CRC Press eBooks · doi:10.3109/9781420086447-6 · Cited by 6
Antibody Fragments Humanization: Beginning with the End in Mind
Aubrey, N., & Billiald, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_10 · Cited by 6
Japanese Regulatory Perspective on Immunogenicity
Hayakawa, T., & Ishii‐Watabe, A. (2011) · Wiley eBooks · doi:10.1002/9781118075685.ch4 · Cited by 6
Therapeutic antibody discovery
Hoover, J. M., Prinslow, E. G., Teigler, J. E., Truppo, M. D., & LaPorte, S. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00023-4 · Cited by 4
Preclinical Immunogenicity Risk Assessement of Biotherapeutics
Jones, T. D., Karle, A. C., & Baker, M. (2015) · CRC Press eBooks · doi:10.1201/b19023-6 · Cited by 3
Sensitization to food or inhalant allergens in pediatric patients. Clinical usefulness of first-level panel tests for specific IgE.
Altrinetti, V., Salmaso, C., Montagna, P., Castellano, E., Cosentino, C., Pesce, G., & Bagnasco, M. (2003) · PubMed · Cited by 3
A novel in silico platform combining data-driven and physics-based models for protein formulation developability assessment
Arsiccio, A., Mutschler, H., Pedro, A. S., Pabstmann, T., Helbig, C., Brandstetter, D., Cerasoli, E., Hawe, A., & Menzen, T. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104196 · Cited by 2
Immunogenicity Lessons Learned from the Clinical Development of Vatreptacog Alfa, A Recombinant Activated Factor VII Analog, in Hemophilia with Inhibitors
Lamberth, K., Weldingh, K. N., Ehrenforth, S., Chéhadé, M. R., & Østergaard, H. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_1 · Cited by 2
Crystal structure of ultra-humanized anti-pTau Fab reveals how germline substitutions humanize CDRs without loss of binding’
Brinth, A. R., Svenson, K., Mosyak, L., Cunningham, O., Hickling, T. P., & Lambert, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-12838-6 · Cited by 2
Safety Assessment Strategies and Predictive Safety of Biopharmaceuticals and Antibody Drug Conjugates
Horner, M. J., Hinrichs, M. J., & Buss, N. A. P. S. (2016) · doi:10.1002/9781119053248.ch3 · Cited by 2
Biopharmaceutics of NCEs and NBEs
Agoram, B. M., Sagawa, K., Shanker, R., & Singh, S. K. (2012) · CRC Press eBooks · doi:10.3109/9781420086447-4 · Cited by 1
In Vitro Assays for Assessing Potential Adverse Effects of Cancer Immunotherapeutics
Li, J., Mitra, M. S., & Rao, G. K. (2020) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-0171-6_12 · Cited by 1
Therapeutic antibody development—Remington chapter
Geist, B. J., Zheng, S., & Xu, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00024-6 · Cited by 1
DELETION OF ANTIBODY ENCODED TOLEROGENIC SIGNALS TO IMPROVE A DENDRITIC CELL TARGETED VACCINE DELIVERY PLATFORM SYSTEM
Aguirre, D. (2014) · doi:10.23860/thesis-aguirre-danielle-2014
Conditions for safe and effective ADEPT treatment
Wilkins, D. K. (2010) · UCL Discovery (University College London)
Análise da imunogenicidade de uma vacina de DNA codificando epitopos CD4 promíscuos e conservados do HIV-1 em camundongos BALB/c e transgênicos para moléculas de HLA classe II
Ribeiro, S. P. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2010.tde-22092010-120821
Prognostic immune markers for chronic allograft injury inrenal transplant recipients
Jham, S. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Sciences, réseaux et cognition après le déluge
Ganascia, J. (2014) · CNRS Éditions eBooks · doi:10.4000/books.editionscnrs.19990
Formulation strategy and tactics for mAbs: not all mAbs are the same
Bee, J. S., Shah, A., Bishop, S. M., & Remmele, R. L. (2015) · doi:10.4155/fseb2013.14.321

Authors: DEGROOT, A., MCMURRY, J., & MOISE, L.
Affiliations: University of Rhode Island (US)
Corresponding author: DEGROOT, A
MOISE, L
ORCID: MCMURRY, J
MOISE, L
Venue: Current Opinion in Pharmacology
Publisher: Elsevier BV
Published: 2008-10
Volume: 8
Issue: 5
Pages: 620-626
ISSN: 1471-4892 (ISSN-L)
DOI: 10.1016/j.coph.2008.08.002
OpenAlex: W2092720388
Cited by: 109
References: 55
Citations by year: 2026: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 5 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 6 · 2012: 14
FWCI: 3.84
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Current Opinion in Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: immunogenicity prediction, therapeutic proteins, antidrug antibodies, in silico prediction tools, preclinical drug development, pharmacokinetics, adverse drug reactions, neutralizing antibodies
MeSH terms: Animals, Epitopes, B-Lymphocytes, Computer Simulation, Drug Evaluation, Preclinical, Humans, Mice, Transgenic, Recombinant Proteins, T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks